VP at MedImmune to Speak at Cytokines Conference Jan 31, 2013 in San Diego, CA
VP at MedImmune to Speak at Cytokines and Inflammation Conference Jan 31 - Feb 1, 2013, San Diego-CA.
- (1888PressRelease) December 13, 2012 - Tomas Mustelin, Vice President of Research, Respiratory, Inflammatory, and Autoimmune Diseases at MedImmune will give a featured presentation on "Targeting Cytokines in the Appropriate Patient Subsets" at the 11th Cytokines and Inflammation Conference to be held in San Diego, CA on January 31 - February 1, 2013 by GTC.
Dr. Mustelin is Vice President and Interim Head of Research at MedImmune. On top of his many responsibilities, he oversees departments for novel therapeutics for grievous respiratory, inflammatory, and autoimmune diseases. He is currently a member of the UCSD Clinical and Translational Research Institute (CTRI) and is interested in opportunities for clinical and translational collaborations. Dr. Mustelin is also an Adjunct Professor at both Burnham Institute and UCSD.
Prior to MedImmune, Dr. Mustelin was Vice President and Site Head of Amgen from 2007 to 2011 where he delivered 11 novel therapeutics into clinical trials. From 1999 to 2007, he was Professor at Burnham Institute and lead an independent, NIH-funded, research group of up to 25 scientists in many areas of cell biology, immunology, cancer, HTS and drug discovery, genetics, genomics, and nanotechnology. In 1999, he was also Professor at Sidney Kimmel Cancer Center where he led another independent, NIH-funded, research group focusing on signal transduction, kinases, phosphatases, in immunity and cancer.
The GTC Cytokines and Inflammation conferences have become an established meeting point for academic scientists and industry clinical developers to exchange their complementary approaches in the field of cytokine biology. The organizations participating are a great selection of innovative medical organizations from academia (City of Hope, NCI, NIH, USC, Sanford-Burnham, Cleveland Clinic, UCLA, University of Florida, etc.), industry (Amgen, Bristol-Myers Squibb, Genentech, HUMIGEN, MedImmune, Biogen Idec, Merck Serono, Novo Nordisk, etc.) and, last but not -by any means- least, the US FDA.
This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of a workshop, this track and three other concurrent tracks:
1) 5th Immunotherapeutics & Immunomonitoring
2) 2nd Allergy & Respiratory Drug Discovery
3) Immunotoxicity & Immunogenicity
4) Workshop: Immune Responses in Tumor Microenvironment
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam